8-KAcquisitions & Dispositions

QUEST DIAGNOSTICS INC 8-K Report, Acquisition Completed (Aug 8, 2005)

Filed August 8, 2005For Securities:DGX

Summary

Quest Diagnostics Incorporated (DGX) has announced a significant development with the execution of a definitive Agreement and Plan of Merger on August 8, 2005. This agreement outlines the acquisition of LabOne, Inc. (LabOne) by Quest Diagnostics through a merger with its wholly-owned subsidiary, Fountain, Inc. (Merger Sub). The transaction is structured as a cash-and-carry deal, where LabOne shareholders will receive $43.90 in cash for each share of LabOne common stock. This acquisition represents a strategic move by Quest Diagnostics to expand its operations and market presence within the diagnostic services sector. Furthermore, the filing also disclosed the appointment of Dr. Jenne K. Britell to Quest Diagnostics' Board of Directors, effective August 6, 2005. Dr. Britell's expertise in corporate leadership and governance, as well as her designation as an "audit committee financial expert," is expected to enhance the Board's oversight capabilities. Investors should view this merger as a material event that could impact Quest Diagnostics' future financial performance, competitive landscape, and strategic direction.

Key Highlights

  • 1Quest Diagnostics to acquire LabOne, Inc. for $43.90 per share in cash.
  • 2The acquisition will be executed through a merger of LabOne with Quest Diagnostics' subsidiary, Fountain, Inc.
  • 3LabOne will become a wholly-owned subsidiary of Quest Diagnostics upon successful completion of the merger.
  • 4The merger is subject to customary closing conditions, including LabOne shareholder approval and regulatory clearance (Hart-Scott-Rodino).
  • 5LabOne may be required to pay Quest Diagnostics a termination fee of $26,500,000 under specific circumstances.
  • 6Dr. Jenne K. Britell appointed to Quest Diagnostics' Board of Directors and Audit and Finance Committee.
  • 7Dr. Britell is considered an independent director and an 'audit committee financial expert'.

Frequently Asked Questions

This 8-K filing announces the entry into a material definitive agreement for Quest Diagnostics to acquire LabOne, Inc., and the appointment of a new independent director to Quest Diagnostics' Board.

The acquisition values LabOne at $43.90 per share in cash. The total transaction value is not explicitly stated in this filing but can be calculated by multiplying the per-share price by the total number of outstanding LabOne shares.

Key conditions include approval from LabOne's stockholders, the absence of any legal prohibitions, the expiration or termination of the Hart-Scott-Rodino waiting period, accuracy of representations and warranties, and material compliance with covenants by both parties.

Dr. Jenne K. Britell has been appointed as a new independent director to Quest Diagnostics' Board of Directors and its Audit and Finance Committee. Her background as Chairman and CEO of Structured Ventures, Inc., along with her designation as an 'audit committee financial expert,' is expected to strengthen the board's oversight and financial expertise.